AIM: To examine whether the detection of either telomerase and its components or high risk human papillomavirus (HPV) are of value in predicting the presence of cervical intraepithelial neoplasia (CIN) grade II/III in women referred because of cervical cytology reports showing at most moderate dyskaryosis. METHODS: Cervical scrapings of 50 women referred with cytological borderline, mild, or moderate dyskaryosis were analysed. Telomerase activity was assessed by a commercially available telomere repeat amplification protocol assay and its components human telomerase RNA (hTR) and human telomerase reverse transcriptase (hTERT) were assessed by reverse transcriptase polymerase chain reaction (PCR). HPV was detected by GP5+/6+ PCR enzyme immunosassay. Histological findings on colposcopy guided biopsies or excised cervical tissue were regarded as the final pathological diagnosis. The sensitivity and specificity for detecting CIN II/III were calculated. RESULTS: Twenty eight women were diagnosed with CIN II/III. Telomerase activity was detected in none, hTR in 88%, hTERT in 23%, and high risk HPV was detected in 79% of these women. As a diagnostic test none of the described analyses combined a sensitivity of at least 90% with a specificity >or= 90%. Despite the small numbers, calculation of the 95% confidence intervals excluded a combined sensitivity and specificity of at least 90% for all of the evaluated parameters. CONCLUSIONS: Neither detection of telomerase or its components, nor detection of high risk HPV seem suitable for the triage of women with borderline, mild, and moderate cytological dyskaryosis.
AIM: To examine whether the detection of either telomerase and its components or high risk human papillomavirus (HPV) are of value in predicting the presence of cervical intraepithelial neoplasia (CIN) grade II/III in women referred because of cervical cytology reports showing at most moderate dyskaryosis. METHODS: Cervical scrapings of 50 women referred with cytological borderline, mild, or moderate dyskaryosis were analysed. Telomerase activity was assessed by a commercially available telomere repeat amplification protocol assay and its components human telomerase RNA (hTR) and humantelomerase reverse transcriptase (hTERT) were assessed by reverse transcriptase polymerase chain reaction (PCR). HPV was detected by GP5+/6+ PCR enzyme immunosassay. Histological findings on colposcopy guided biopsies or excised cervical tissue were regarded as the final pathological diagnosis. The sensitivity and specificity for detecting CIN II/III were calculated. RESULTS: Twenty eight women were diagnosed with CIN II/III. Telomerase activity was detected in none, hTR in 88%, hTERT in 23%, and high risk HPV was detected in 79% of these women. As a diagnostic test none of the described analyses combined a sensitivity of at least 90% with a specificity >or= 90%. Despite the small numbers, calculation of the 95% confidence intervals excluded a combined sensitivity and specificity of at least 90% for all of the evaluated parameters. CONCLUSIONS: Neither detection of telomerase or its components, nor detection of high risk HPV seem suitable for the triage of women with borderline, mild, and moderate cytological dyskaryosis.
Authors: M V Jacobs; P J Snijders; A J van den Brule; T J Helmerhorst; C J Meijer; J M Walboomers Journal: J Clin Microbiol Date: 1997-03 Impact factor: 5.948
Authors: A G Bodnar; M Ouellette; M Frolkis; S E Holt; C P Chiu; G B Morin; C B Harley; J W Shay; S Lichtsteiner; W E Wright Journal: Science Date: 1998-01-16 Impact factor: 47.728
Authors: P J Snijders; M van Duin; J M Walboomers; R D Steenbergen; E K Risse; T J Helmerhorst; R H Verheijen; C J Meijer Journal: Cancer Res Date: 1998-09-01 Impact factor: 12.701
Authors: M A Nobbenhuis; J M Walboomers; T J Helmerhorst; L Rozendaal; A J Remmink; E K Risse; H C van der Linden; F J Voorhorst; P Kenemans; C J Meijer Journal: Lancet Date: 1999-07-03 Impact factor: 79.321
Authors: G B Wisman; H Hollema; S de Jong; J ter Schegget; S P Tjong-A-Hung; M H Ruiters; M Krans; E G de Vries; A G van der Zee Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544
Authors: S Bravaccini; M A Sanchini; A Amadori; L Medri; L Saragoni; D Calistri; F Monti; A Volpi; D Amadori Journal: J Clin Pathol Date: 2005-09 Impact factor: 3.411
Authors: Jillian de Wilde; Jan M Kooter; Renée M Overmeer; Debbie Claassen-Kramer; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen Journal: BMC Cancer Date: 2010-06-09 Impact factor: 4.430
Authors: Kerstin Heselmeyer-Haddad; Viktor Janz; Philip E Castle; Nadia Chaudhri; Nicole White; Kim Wilber; Larry E Morrison; Gert Auer; Frances H Burroughs; Mark E Sherman; Thomas Ried Journal: Am J Pathol Date: 2003-10 Impact factor: 4.307